April 26, 2012
Sosei Group Corporation announced on April 24 that the new COPD (chronic obstructive pulmonary disease) treatment QVA149 (indacaterol maleate/glycopyrronium bromide) has met all its primary endpoints in the fourth clinical trial in the PIII IGNITE program conducted by its licensee...read more